Skip to content
cccskills
FreePublished on GitHub

es-determine-tanner-stage-pubertal-suppression

Assesses Tanner stage to determine if physical changes of puberty have begun (stage G2/B2 or higher) for considering pubertal suppression. Triggered when a clinician evaluates pubertal development in an adolescent patient.

The English summary is being prepared. Showing the original description.

See how to install

Files included (1)

  • SKILL.md2.2 KB

SKILL.md (original)

Review the instructions the agent will receive before you install.

Determine Tanner stage for pubertal suppression eligibility

STEP 1 — Gather Information

Obtain the patient's sex assigned at birth and perform a focused physical examination: for individuals assigned female, assess breast development using Tanner stages; for individuals assigned male, assess testicular volume and penile size using Tanner stages. Record the highest breast or genital Tanner stage observed.

STEP 2 — Rule In / Rule Out

Determine whether the observed Tanner stage is G2/B2 or higher. If yes, rule in that puberty has begun; if the stage remains at 1 (prepubertal), rule out puberty onset.

STEP 3 — Classify or Stratify

Classify the patient as eligible for consideration of pubertal suppression if Tanner stage is G2/B2 or higher (≥2); classify as not eligible if Tanner stage is 1.

STEP 4 — Decide

If eligible (≥2), refer the patient to a multidisciplinary team for shared decision‑making regarding initiation of gonadotropin‑releasing hormone agonist suppression; if not eligible (stage 1), schedule a follow‑up assessment in 3 to 6 months to re‑evaluate Tanner progression.

Clinical Guardrails / Mimics / Pitfalls

Do not confuse adrenarche (pubic/axillary hair) with gonadarche; avoid relying solely on patient‑reported changes; be aware that obesity can mimic breast tissue in assigned females; do not delay assessment based on age alone; consider obtaining LH/FSH or ultrasensitive estradiol/testosterone if physical findings are ambiguous.

Concrete Clinical Example

A 12‑year‑old assigned female presents with breast budding (Tanner stage 2) and no pubic hair. The clinician records Tanner stage G2, rules in puberty onset, classifies as eligible, and refers to the multidisciplinary team for discussion of GnRH agonist suppression.

Source: Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons, Endocrine Society, 2017, doi:10.1210/jc.2017-01658

Reviews

No reviews yet. Tell others what you thought.

Comments

No login needed. Share how it worked for you, ask a question, or note where it did not run.

No comments yet. Be the first to write one.

Comments are published right away. Do not include personal information such as email addresses or phone numbers. Up to 2 URLs.

0 / 1,000 characters

This form is protected by reCAPTCHA, and the Google Privacy Policy and Terms of Service apply.

More skills from this repository

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

See all skills by dromlakhani

Report a problem with this skill